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Triple-negative breast cancer (TNBC) is considered
incurable with currently available treatments, high-
lighting the need for therapeutic targets and predic-
tive biomarkers. Here, we report a unique role for
Bcl-2-associated athanogene 2 (BAG2), which is
significantly overexpressed in TNBC, in regulating
the dual functions of cathepsin B as either a pro- or
anti-oncogenic enzyme. Silencing BAG2 suppresses
tumorigenesis and lung metastasis and induces
apoptosis by increasing the intracellular mature
form of cathepsin B, whereas BAG2 expression in-
ducesmetastasis by blocking the auto-cleavage pro-
cessing of pro-cathepsin B via interaction with the
propeptide region. BAG2 regulates pro-cathepsin
B/annexin II complex formation and facilitates the
trafficking of pro-cathespin-B-containing TGN38-
positive vesicles toward the cell periphery, leading
to the secretion of pro-cathepsin B, which induces
metastasis. Collectively, our results uncover BAG2
as a regulator of the oncogenic function of pro-
cathepsin B and a potential diagnostic and therapeu-
tic target that may reduce the burden of metastatic
breast cancer.INTRODUCTION
Among the molecular subtypes of breast cancer, triple-negative
breast cancer (TNBC) is an extremely aggressive subtype that is
correlated with a poor prognosis and high mortality rates despite2952 Cell Reports 21, 2952–2964, December 5, 2017 ª 2017 The Au
This is an open access article under the CC BY-NC-ND license (http://systemic therapy; TNBC is also a heterogeneous disease
compared to either luminal or HER2-enriched subtypes (Foulkes
et al., 2010; Masuda et al., 2013). Although several clinical trials
targetingmolecules specific to TNBC, including poly ADP-ribose
polymerase (PARP), epidermal growth factor receptor (EGFR),
and Src tyrosine kinase, have been conducted, they have not
led to significant improvements in the treatment of patients
with TNBC (Crown et al., 2012; Hudis and Gianni, 2011). Thus,
there is an urgent need to discover effective therapeutic targets
that improve disease outcome and prognosis in patients with
TNBC and serve to improve our understanding of the molecular
basis for TNBC development, progression, and metastasis.
As a member of the Bcl-2-associated athanogene (BAG)
domain family with anti-apoptotic activity, BAG2 has been
described as a negative regulator of the chaperone-associated
ubiquitin ligase C terminus of Hsc70-interacting protein (CHIP)
that participates in the ubiquitin-mediated proteasomal degra-
dation of misfolded substrate proteins (Arndt et al., 2005; Dai
et al., 2005). The main effect of BAG2 on the control of protein
quality through inhibition of CHIP activity is linked to neuro-
degenerative disorders and autosomal-recessive disorders
through protein stabilization of chaperone clients, such as
PINK1 and CFTR (Arndt et al., 2005; Qu et al., 2015). However,
the role of BAG2 in cancer has not been well characterized,
and its role in the regulation of tumorigenesis remains controver-
sial. It has been reported that BAG2 expression is increased
in proteasome-inhibitor-induced apoptosis, and BAG2 knock-
down partially inhibits cell death in thyroid carcinoma cells
exposed to the proteasome inhibitor MG132, suggesting that
BAG2 may have pro-apoptotic activity (Wang et al., 2008). How-
ever, considerable attention has recently been paid to the find-
ings that overexpression of BAG2, like BAG1 and BAG3, can
promote tumorigenesis. BAG2 overexpressed in various cancer
cells promotes nuclear accumulation of mutant p53 by directlythor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
binding to mutant p53 and inhibit its degradation by E3 ligase
MDM2, suggesting that BAG2 drives tumor growth by enhancing
the function of the mutant p53 protein (Yue et al., 2015). Despite
this findings, the precise role of BAG2 in cancer progression and
metastasis has not been extensively investigated, but these data
suggest an important gap in our knowledge, especially in the
context of breast cancers.
Cathepsin B (CTSB), a lysosomal cysteine protease possess-
ing both endo- and exo-peptidase activity, is considered
to participate in protein turnover (Mort and Buttle, 1997).
CTSB is synthesized as an inactive/immature pro-form enzyme
(41/43 kDa), which is converted to the active single-chain form
(31 kDa) or double-chain form (heavy chain, 25/26 kDa; light
chain, 5 kDa) through proteolytic processing of a 62-amino-
acid propeptide of the N terminus. Aberrant expression/activity
of CTSB has often been linked to progression and metastasis
of malignant tumors, especially in breast cancers (Joyce et al.,
2004; Withana et al., 2012). The intracellular trafficking of
CTSB is frequently altered in malignant tumors, resulting in the
secretion of the pro-form of CTSB. Secreted pro-CTSB is acti-
vated by cathepsin D, elastase, and by itself in acidic tumor en-
vironments, leading to the activation of other proteases, such as
urokinase-type plasminogen activator (uPA) and matrix metallo-
proteinases (MMPs), consequently facilitating tumor progres-
sion and metastasis (Olson and Joyce, 2015). Moreover, it was
reported that transgenic overexpression of human CTSB led
to enhanced tumor growth and lung metastasis, whereas Ctsb-
deficient mice showed delayed tumor progression and reduced
metastatic colonies in the lung (Sevenich et al., 2011; Vasiljeva
et al., 2008). However, it has also been recognized that mature
CTSB is normally localized in lysosomes, where it functions in
protein turnover as an initiator protease during lysosome-medi-
ated autophagy/apoptosis, indicating a pro-apoptotic role for
cytosolic CTSB (Bhoopathi et al., 2010; Foghsgaard et al.,
2001). Although CTSB has been extensively studied in a wide va-
riety of human cancers, the molecular basis regulating its dual
functions as either a pro-oncogenic or pro-apoptotic enzyme is
poorly understood. Furthermore, regulators that control the
dual functions of CTSB in cancer progression remain to be
identified.
Here, we show that BAG2 promotes cancer progression by
regulating the dual function of CTSB in TNBC cells, implicating
the potential for BAG2 to serve as a specific target for the treat-
ment of TNBC.
RESULTS
Co-chaperone BAG2 Is Specifically Overexpressed in
TNBC Cells
In order to identify molecular targets associated with TNBC
progression, we initially performed transcriptome analysis us-
ing RNA sequencing in breast cancer cell lines classified as
either the luminal subtype (MCF-7, T47D, and ZR-75B) or
TNBC (MDA-MB-231 and Hs578T). We found that BAG2 was
specifically overexpressed in TNBC cells compared to luminal
breast cancer cell lines (Figure 1A). RT-PCR and immunoblot
analyses supported the RNA-sequencing data (Figure 1B).
Furthermore, gene expression analysis of a public microarraydataset (GEO: GSE41313) in 52 breast cancer cell lines
showed that expression of BAG2 was significantly higher in
TNBC cells than in luminal subtypes (p < 0.0001; Figure 1C)
(Riaz et al., 2013). To examine this more precisely, we analyzed
BAG2 expression in different subtypes using RNA-sequencing
datasets of breast cancer patients obtained from Genomic
Data Commons (GDC). Notably, a significantly higher level of
BAG2 expression was observed in TNBC patients compared
to normal-like, luminal A, luminal B, and HER2-enriched pa-
tients (p < 0.0001; Figure 1D). We next examined the expres-
sion level of BAG2 protein and mRNA in human primary breast
tumor specimens by immunohistochemistry staining and qRT-
PCR. Consistently, expression of BAG2 protein was remark-
ably elevated in the tumor compartments of TNBC tissues (Fig-
ure 1E), and BAG2 mRNA was significantly increased in TNBC
tissues (p = 0.0004; Figure 1F). We also investigated whether
other BAG protein family members were overexpressed in
TNBC subtypes using The Cancer Genome Atlas (TCGA)
datasets and public microarray datasets (GEO: GSE41313,
GSE2034, and GSE5460) (Bos et al., 2009; Lu et al., 2008).
Interestingly, only BAG2 expression was significantly upregu-
lated in TNBC cells and patients compared to the luminal sub-
types (Figure S1). Next, to assess whether BAG2 expression is
associated with breast cancer progression, we investigated
the expression level of BAG2 in the MCF10A series of cell
lines, which mimic different stages of breast cancer progres-
sion and comprise immortalized normal-like mammary epithe-
lial cells (MCF10A) to highly metastatic breast cancer cells
(MCF10CA1a). More strikingly, BAG2 mRNA and protein
expression was increased in metastatic breast cancer cells
(Figure 1G). Taken together, these results suggest that BAG2
is strongly associated with tumor progression of TNBC.
Overexpression of BAG2 Is Strongly Correlated with
Poor Clinical Outcomes
To address the functional significance of the association of
BAG2 expression with clinicopathological parameters in breast
cancer patients, we performed immunohistochemical staining
of breast cancer tissue microarrays (TMAs) and scored accord-
ing to the staining intensity (Figure 2A). Statistical analysis re-
vealed the clinicopathologic relevance of high BAG2 expres-
sion in tumor grade (p < 0.001), ER or PR expression status
(p < 0.001), HER2 overexpression status (p = 0.021), and
the subtypes (p < 0.001) (Figure 2B; Table S1). Notably,
BAG2 expression was strongly associated with TNBC (40 of
135 [29.7%]; p < 0.001) (Figure 2C). We further found that
BAG2 overexpression was significantly correlated with poorer
breast-cancer-specific survival (BSS; p = 0.048), recurrence-
free survival (RFS; p = 0.0359) (Figure 2D), and distant metas-
tasis-free survival (DMFS; p = 0.02; Figure S2A) in Kaplan-Meier
analysis. Moreover, patients with lymph-node-positive breast
cancer demonstrated a significant association between high
BAG2 expression and unfavorable RFS (p = 0.0046; Figure 2E)
and DMFS (p = 0.0029; Figure S2B), whereas no significant sur-
vival disadvantage was shown in patients with lymph-node-
negative breast cancer. Consistent with our cohort studies,
public meta-analyses using Kaplan-Meier Plotter software
(Gy}orffy et al., 2014), which provides survival information inCell Reports 21, 2952–2964, December 5, 2017 2953
Figure 1. BAG2 Is Specifically Overexpressed in TNBC Cells and Primary TNBC Tissues
(A) Volcano plot of differential expression between luminal (MCF-7, T47D, and ZR-75B) and TNBC (MDA-MB-231 and Hs578T) cell lines using RNA sequencing.
(B) RT-PCR and immunoblot analysis of BAG2 mRNA and protein expression in luminal and TNBC cell lines.
(C) Scatter dot plots of BAG2 expression in 52 breast cancer cell lines using published microarray datasets.
(D) Box plots ofBAG2 expression in different subtypes of breast cancer and normal tissues obtained fromRNA-sequencing datasets of Genomic Data Commons
(GDC).
(E) Histological analysis of BAG2 and ERa in luminal (top) and TNBC (bottom) breast cancer tissue.
(F) qRT-PCR of BAG2 gene expression in 12 luminal tissues and 6 TNBC tissues.
(G) RT-PCR and immunoblot analysis of BAG2 mRNA and protein expression in MCF10A-derived cell lines representing degrees of metastatic potential.more than 3,000 breast cancer patients, also revealed that pa-
tients with high BAG2 expression had shorter survival times
compared to those with low BAG2 expression (Figures S2D–
S2F). In addition, Cox multivariate regression analysis exhibited
significantly increased hazard ratio (HR) in patients with high
BAG2 expression for predicting BSS (p = 0.035; HR = 2.084;
95% confidence interval [CI], 1.002–4.4336), RFS (p = 0.01;
HR = 2.311; 95% CI, 1.227–4.355) (Figure 2F), and DMFS
(p = 0.012; HR = 2.362; 95% CI, 1.209–4.614) (Figure S2C),
suggesting that BAG2 overexpression is an independent prog-
nostic factor for breast cancer patients’ chances of survival.
Taken together, these findings indicate that BAG2 is strongly2954 Cell Reports 21, 2952–2964, December 5, 2017correlated with poor clinical outcomes and may serve as a pos-
itive predictive factor for the risk of mortality in breast cancers.
BAG2 Facilitates Tumor Growth and Lung Metastasis in
TNBC Cells
To identify BAG2-associated pathways in breast cancers, we
first performed gene set enrichment analysis (GSEA) on
the TCGA breast cancer patient samples (N = 1,166). GSEA
analysis revealed that high BAG2 expression was positively
associated with the genes involved in pathways driving
breast cancer progression, such as cell proliferation (false
discovery rate [FDR] = 0.006; p < 0.001) and cell migration
Figure 2. Overexpression of BAG2 Has Clinical Relevance and Prognostic Value
(A) Representative images of IHC staining of BAG2 on paraffin-embedded TMAs of breast cancer tissues.
(B) Associations between high BAG2 expression and clinical parameters.
(C) Pie charts showing the percentages of low and high BAG2 expression in patients with different breast cancer subtypes.
(D) Kaplan-Meier analysis showing breast-cancer-specific survival and recurrence-free survival depending on BAG2 expression level.
(E) Kaplan-Meier analysis showing the association between BAG2 expression and recurrence-free survival according to the lymph node status.
(F) Cox proportional hazards regression model.(FDR < 0.0001; p < 0.001) (Figure 3A). Because BAG2 expression
was specifically increased in TNBC cells, we generated BAG2-
depleted TNBC cells (Hs578T, MDA-MB-231, and MCF10CA1a)
to verify the physiological function of BAG2 in the cancer pro-
gression of TNBC cells in vitro and in vivo (Figure S3A). BAG2
knockdown demonstrated anti-proliferative effect in all three
TNBC cell lines (Figures 3B and S3B). We further examined
whether depletion of BAG2 affected the tumorigenic capacity
of TNBC cells in vivo through subcutaneous injection of three
different TNBC cells into the flank of immunodeficient mice.Knockdown of BAG2 decreased the ability of TNBC cells to
form tumors, indicating that BAG2 is required to reinforce tumor-
igenicity in vivo (Figures 3C and 3D).
As transforming potential is generally associated with
enhanced invasion capability for metastasis of tumor cells, we
next investigated cell invasion in vitro in BAG2-depleted TNBC
cells. Cell invasion was significantly reduced by BAG2 knock-
down (Figure S3C). We further observed that tail vein injection
of BAG2-depleted MDA-MB-231 and MCF10CA1a cells with a
luciferase reporter resulted in a significant reduction of lungCell Reports 21, 2952–2964, December 5, 2017 2955
Figure 3. Depletion of BAG2 Significantly Suppresses the Tumorigenicity and Lung Metastasis of TNBC Cells
(A) Identification of gene sets enriched by GSEA in breast cancer patients with BAG2high versus BAG2low obtained from TCGA.
(B) Cell doublings of BAG2-depleted TNBC cells.
(C and D) Tumor formation (C) and growth (D) of control and BAG2-deficient TNBC cells subcutaneously injected into the flanks of non-obese diabetic/severe
combined immunodeficiency (NOD/SCID) mice (n = 6).
(E) Representative biolayer interferometry (BLI) imaging of BALB/c mice (n = 10) showing primary tumors and spontaneous lung metastases generated by control
or BAG2-depleted 4T1-Luc cells.
(F) Tumor volume curves showing primary tumor growth at 5 weeks postinjection.
(G) Representative whole-lung image stained with India ink showing metastatic nodules (top) and scatterplot on the number of spontaneous lung metastatic
nodules (bottom).
(H) Representative image of H&E staining of lungs showing spontaneous lung metastatic nodules.
(I) Representative BLI imaging of NOD/SCID mice (n = 6) showing lung metastasis from control and BAG2-depleted MCF10CA1a-Luc cells along with BAG2
rescue.
(J) Representative image of lungs stained with India ink.
(K) Representative image of H&E staining of lungs showing metastatic nodules.
(L) Kaplan-Meier survival curves of mice from (I).metastasis and prolonged survival in immunodeficient mice (Fig-
ures S3D–S3I). Consistent with previous observations, we found
that Bag2 knockdown decreased invasiveness of 4T1-Luc cells,
which are highly metastatic murine breast cancer cells (Figures
S3J and S3K). Moreover, orthotopic transplantation of Bag2-
deficient 4T1-Luc cells into the mammary fat pad resulted in a
significant inhibition of primary tumor growth as well as sponta-
neous lung metastasis (Figures 3E–3H). To ensure the possibility
that BAG2 may directly influence lung metastasis of TNBC2956 Cell Reports 21, 2952–2964, December 5, 2017cells, we rescued BAG2-depleted MCF10CA1a-Luc cells via
stable overexpression of BAG2-specific small hairpin RNA
(shRNA)-resistant Myc-tagged BAG2 (Figures S3L). Interest-
ingly, BAG2-rescued cells significantly restored attenuated
invasion capability of BAG2-depleted cells to the control levels
(Figure S3M). In accordance with this observation, the re-intro-
duction of BAG2 prominently rescued BAG2 knockdown effects
of decreased lung metastasis and prolonged survival of mice
(Figures 3I–3L). Taken together, these in vitro and in vivo results
Figure 4. Depletion of BAG2 Induces Lysosomal-Mediated Cell Death by Releasing the Single-Chain Form of CTSB into the Cytosol and
Impairing Lysosome Biogenesis
(A) Venn diagram showing the number of downregulated spots by BAG2 knockdown at the intersection of three different TNBC cell lines through 2-DE analysis.
(B) Magnified 2-DE gel image displaying the spots of CTSB (double-chain form; red) and BAG2 (blue) proteins.
(C) Immunoblot analysis (top) and qRT-PCR (bottom) of CTSB and BAG2 in control and BAG2-depleted TNBC cells.
(D) Immunoblot analysis of MDA-MB-231 cells treated with MG132.
(E) Pro-CTSB biogenesis in control and BAG2-depleted MDA-MB-231 cells.
(F) Densitometry of the pro-CTSB bands in (E) using ImageJ software.
(G) Immunoblot analysis of control and BAG2-depleted TNBC cells.
(H) Immunoblot analysis of MCF10CA1a-Luc cells stably expressing control shRNA, BAG2 protein, BAG2-specific shRNA, or BAG2 rescue.
(I) CTSB activity of control and BAG2-depleted TNBC cells.
(J) CTSB activity of each fraction eluted from (H).
(K) Focus-forming assay of BAG2-depleted TNBC cells.
(L) Immunoblot analysis of control and BAG2-deficient cells treated with or without Leu-Leu-OME.
(M) Immunofluorescence analysis of endogenous BAG2 (green) and LAMP-1 (red) in control and BAG2-depleted MDA-MB-231 cells.strongly suggest that BAG2 is critical for tumorigenesis andmet-
astatic progression of TNBC.
Knockdown of BAG2 Induces Cell Death by Impairing
CTSB Activation
In order to assess the molecular mechanism behind BAG2-
mediated TNBC progression and to ascertain the BAG2 client
proteins, we performed 2-dimensional electrophoresis (2-DE)
analysis using control and BAG2-depleted TNBC cells. Through
comparative analysis, we identified 44 downregulated spots by
BAG2 knockdown at the intersection of three different TNBC
cells (Figures 4A). Through mass spectrometric analysis, thedouble-chain (DC) form of cathepsin B (CTSB) was identified
as the highest-ranked downregulated protein (Figures 4B). First,
we found that BAG2 knockdown decreased protein expression
of DC CTSB without affecting mRNA expression (Figure 4C).
Most interestingly, among the pro- (41/43 kDa), single-chain
(SC; 31 kDa), and DC (24/25 kDa) forms of CTSB, SC CTSB
was markedly increased by BAG2 knockdown, whereas DC
CTSB was decreased. We further examined whether the
decrease of DCCTSB byBAG2 knockdownwas induced by pro-
teasomal degradation. MG132 treatment did not increase pro-
tein stability of DC CTSB in both control and BAG2-depleted
MDA-MB-231 cells, indicating that BAG2 may be associatedCell Reports 21, 2952–2964, December 5, 2017 2957
with the cleavage processing of pro-CTSB rather than the pro-
teasomal degradation (Figure 4D). Because pro-CTSB is
converted into the mature SC and DC forms through rapid
biogenesis, we speculated that immunoblotting analysis might
not be able to detect BAG2-knockdown-induced changes in
the total expression of pro-CTSB. Therefore, we evaluated early
events in pro-CTSB biogenesis by pulse-chase experiments.
Indeed, BAG2 depletion markedly decreased the level of labeled
pro-CTSB in a time-dependent manner compared to control
cells, implying the rapid conversion of pro-CTSB into mature
SC CTSB (Figures 4E and 4F). Furthermore, we investigated
whether BAG2 knockdown affected cleavage processing of
other lysosomal enzymes such as cathepsin D and legumain.
Interestingly, mature form of cathepsin D, which is active, was
decreased by BAG2 depletion in Hs578T and MCF10CA1a cells
but increased in MDA-MB-231 cells. However, depletion of
BAG2 did not influence the cleavage processing of legumain,
suggesting that BAG2 may specifically regulate pro-CTSB
cleavage processing in TNBC cells, at least among lysosomal
enzymes (Figure S4A). In addition, it has been known that
BAG2 modulates Hsp70/Hsc70- and Hsp90-mediated chap-
erone expression/activity through direct interaction (Arndt
et al., 2005). Unlike BAG2, depletion of Hsc70/Hsp90 did not
influence the SC form of CTSB, indicating that BAG2-mediated
cleavage of pro-CTSB may be independent of Hsp70/Hsc70-
and Hsp90-mediated chaperone expression (Figures S4C–S4E).
We next investigated whether BAG2 knockdown affected
lysosomal-mediated cell death by increasing intracellular mature
SCCTSB. Interestingly, BAG2 knockdown increased expression
of cleaved caspase-3, a pivotal mediator of apoptosis, without
affecting LC3B expression, a marker of autophagy induction
(Figure 4G). This was further corroborated by the finding that
re-introduction of BAG2 to BAG2-deficient MCF10CA1a cells
significantly reduced the expression of active casepase-3 and
mature SC CTSB (Figure 4H). Because the activity of lysosomal
mature CTSB plays a role in the activation of caspase-3, we
next tested the activity of CTSB by using synthetic Arg-Arg, a
substrate sequence for mature CTSB. CTSB activity was signif-
icantly increased by BAG2 knockdown (Figure 4I), and intracel-
lular active CTSB was localized throughout the cytoplasm of
BAG2-deficient cells compared to control cells (Figure S5A).
Furthermore, BAG2 regulation of CTSB activity was further
confirmed by observing that increased CTSB activity by BAG2
knockdown was significantly attenuated in BAG2-rescued cells
(Figure 4J). Considering that both mature SC and DC forms of
CTSB generally possess proteolytic activity, we examined intra-
cellular CTSB activity using the fractions obtained from size
exclusion chromatography to determine the active form of
mature CTSB in BAG2-deficient cells. Indeed, in control cells,
fractions 7–8, in which the DC form was detected, exhibited
lower CTSB activity than fractions 9–11, in which the SC form
was observed, suggesting that the DC form of CTSB is less
active than the SC form (Figures S5B and S5C). We next inves-
tigated foci formation of MDA-MB-231 cells using CA-074 Me,
a specific cell-permeable inhibitor of active CTSB, to see
whether BAG2-knockdown-mediated activation of SC CTSB
directly induces inhibition of cell growth. Reduction of foci forma-
tion by BAG2 depletion was moderately rescued by CA-074 Me2958 Cell Reports 21, 2952–2964, December 5, 2017in BAG2-deficient cells (Figure 4K). Furthermore, to examine
whether BAG2 depletion induces the release of active SC
CTSB into the cytosol through lysosomal leakage, we examined
the cytosolic active SC CTSB using Leu-Leu-OME, a lysosomo-
tropic agent. The increase in expression levels of cytosolic SC
CTSB and cleaved caspase-3 after BAG2 knockdown was
similar to that produced by Leu-Leu-OME in control cells (Fig-
ure 4L). Also, foci formation was decreased by Leu-Leu-OME
in both control and BAG2-deficient cells (Figure S6A). Collec-
tively, these results indicate that BAG2 may maintain TNBC
cell survival by inhibiting the release of active SC CTSB into
the cytosol and subsequent caspase-3-mediated apoptosis
through blockage of lysosomal leakage.
As pro-CTSB is activated by auto-catalytic processing in an
acidic environment, we next tested whether BAG2-regulated
auto-catalytic processing of pro-CTSB was dependent on intra-
cellular lysosomal acidification. BAG2 depletion created an
enhanced acidic environment, as shown by increased acridine-
orange-induced red fluorescence staining under exciting blue
light (Figure S6B), and bafilomycin A1, an inhibitor of vacuolar
H+-ATPase, suppressed the BAG2-depletion-mediated increase
in SC CTSB (Figure S6C). Interestingly, depletion of BAG2
caused a significant increase in lysosomal-associated mem-
brane protein 1 (LAMP-1) along with SC CTSB (Figures 4G).
Consistent with this observation, confocal microscopy imaging
showed that BAG2 knockdown dramatically increased the abun-
dance of LAMP-1-positive lysosomes and induced the accumu-
lation of LAMP-1 around the perinuclear region, indicating that
BAG2 depletion may inhibit TNBC cell growth by impairing lyso-
some biogenesis (Figures 4M and S6D). Taken together, our
findings suggest that knockdown of BAG2 induces apoptosis
through cytosolic release of increased amounts of the mature
SC form of CTSB and impairs lysosome biogenesis, thereby
positioning BAG2 as an important negative regulator in intracel-
lular active SC-CTSB-mediated apoptosis in TNBC cells.
BAG2 Prevents Auto-cleavage of Pro-CTSB by Binding
to the Propeptide Region
We next sought to elucidate the underlying mechanism by which
BAG2 regulates the auto-cleavage processing of pro-CTSB. To
investigate whether BAG2 interacts with pro-CTSB, we first per-
formed an in situ proximity ligation assay (PLA). Confocal imag-
ing showed that BAG2 interacted with CTSB in the cytoplasm
(Figure 5A). Because the CTSB antibody recognizes both pro-
CTSB and the mature forms of CTSB (SC and DC), we also
performed size exclusion chromatography and an immunopre-
cipitation assay to identify the specific form of CTSB to which
BAG2 bound. Size exclusion chromatography revealed that
BAG2 and pro-CTSB remained in the same fraction (sample 5
and 6), whereas the SC or DC forms did not, suggesting that
BAG2andpro-CTSBco-exist in the samecomplexes (Figure 5B).
Furthermore, anti-BAG2 immunocomplexes demonstrated an
endogenous interaction with pro-CTSB, but not with SC, DC
CTSB (Figure 5C), and other lysosomal cathepsin family mem-
bers, such as cathepsin D (Figure S4B). Considering that pro-
CTSB contains the propeptide region (PPR), which includes
the cleavage site for its conversion to the SC CTSB, we
assumed that BAG2 might interact with the PPR of pro-CTSB
Figure 5. BAG2 Regulates Auto-cleavage of Pro-CTSB by Binding to the Propeptide Region
(A) Confocal image of in situ PLA showing the interaction (red) between BAG2 and CTSB in MDA-MB-231 cells.
(B) Size distribution of CTSB following size exclusion chromatography.
(C) Immunoprecipitation assay showing the endogenous interaction between BAG2 and CTSB in TNBC cells.
(D) GST pull-down assay of Myc-tagged BAG2 bound to glutathione S-transferase (GST)-fused deletion mutants of the propeptide region of pro-CTSB.
(E) The predicted interaction sites determined by PSIVER software.
(F) The putative BAG2-binding sites (Y54, R57, and L58) on a predicted three-dimensional structure of CTSB PPR.
(G) The conserved sequence in CTSB PPR among different mammalian species.
(H) Immunoprecipitation assay showing BAG2-binding region in CTSB PPR.
(I) Peptide sequences of scramble or CTSB PPR (48–62).
(J) Immunoprecipitation assay showing the inhibitory effect of CTSB PPR (48–62) peptide.
(K) Immunoblot analysis of MDA-MB-231 cells treated with CTSB PPR (48–62) peptide.
(L) Transwell migration assay showing the inhibitory effect of cell migration of CTSB PPR (48–62) peptide in MDA-MB-231 cells.to regulate cleavage processing. Indeed, an immunoprecipita-
tion assay showed that BAG2 specifically bound to the PPR of
pro-CTSB (Figures S7A and S7B). We further identified that res-
idues 51–58 in the second alpha helix of the PPR, which contains
the intermediate starting site of auto-cleavage processing, inter-
acted with BAG2, whereas residues 59–80 in the PPR, which
include the major cleavage site of pro-CTSB, failed to interact
with BAG2 (Figure 5D). Moreover, we found that pro-CTSB
bound to the BAG domain of BAG2, which harbors the dual
functions of nucleotide exchange and client binding, and thecoiled-coil domain of BAG2 failed to interact with pro-CTSB (Fig-
ure S7C). In parallel with this approach, we attempted to predict
the specific protein-binding sites in the PPR of pro-CTSB using
PSIVER software (Murakami andMizuguchi, 2010). We identified
a cluster of three candidate binding residues (Y54, R57, and
L58), which were oriented in the same direction, displayed
the highest score (R0.56) (Figures 5E and 5F), and are
highly conserved in different mammalian species (Figure 5G).
Interestingly, the mutation in the PPR of pro-CTSB markedly
reduced its interaction with BAG2, indicating that the Y54,Cell Reports 21, 2952–2964, December 5, 2017 2959
R57, and L58 residues are critical for the interaction between
BAG2 and pro-CTSB (Figure 5H). Next, we investigated the pos-
sibility of a cell-penetrating peptide of CTSB PPR as a dominant-
negative inhibitor targeting the interaction between BAG2 and
pro-CTSB (Figure 5I). Indeed, immunoprecipitation experiments
revealed that the peptide CTSB PPR (48–62) completely in-
hibited the complex formation of endogenous BAG2 with pro-
CTSB (Figure 5J). In addition, treatment of the peptide CTSB
PPR (48–62) markedly induced not only an increase in active
caspase-3 and SC CTSB but also a decrease in the ability of
MDA-MB-231 cells to migrate (Figures 5K and 5L). Taken
together, these results suggest that BAG2 prevents auto-cleav-
age processing of pro-CTSB through direct interaction with the
PPR of pro-CTSB, eventually inhibiting the conversion of CTSB
from the immature pro-form to the mature SC form.
BAG2 Interacts with the Pro-CTSB/Annexin II Complex
and Regulates Pro-CTSB Secretion on the Surface of
TNBC Cells
Studies have shown that the interaction between pro-CTSB and
the annexin II tetramer on the surface of tumor cell plays an
important role in extracellular proteolysis, which promotes tumor
progression and metastasis (Mai et al., 2000; Olson and Joyce,
2015). We hypothesized that BAG2 might control the activation
of pro-CTSB on the cell surface of TNBC cells by regulating
the pro-CTSB/annexin II complex. To test our hypothesis, we
initially analyzed the biotinylated cell surface fractions by immu-
noblotting. BAG2 knockdown led to a significant reduction in
pro-CTSB expression on the membrane and cell surface (Fig-
ure 6A). Most interestingly, BAG2, pro-CTSB, and SC CTSB
were all localized on the cell surface. Thus, we examined
whether BAG2 bound to the cell-surface complex of pro-
CTSB/annexin II. Anti-CTSB immunocomplexes demonstrated
an endogenous interaction with BAG2 along with annexin II (Fig-
ure 6B), and the PPR of CTSB was responsible for the complex
formation with BAG2 and annexin II, as well as S100A10, a light
chain of annexin II (Figures 6C–6F). Interestingly, BAG2 regu-
lated the complex formation of pro-CTSB and annexin II on the
cell surface, which may ultimately facilitate the activation of
pro-CTSB (Figure 6G). Next, to further determine whether
BAG2 regulates pro-CTSB at the surface of TNBC cells, we
treated MDA-MB-231 cells with Versene solution to disrupt
Ca2+-dependent annexin II. Interestingly, the Versene-wash
fractions of control cells contained pro-CTSB, annexin II, and
BAG2, whereas BAG2 knockdown significantly reduced the level
of detached pro-CTSB from the cell surface, but not that of
annexin II, suggesting that BAG2 may regulate the secretion of
pro-CTSB (Figure 6H). Secreted CTSB activates MMPs by
inducing their cleavage, and MMPs in turn degrade components
of the extracellular matrix (ECM). We observed decreased
MMP-2 activity but unaffected protein levels of endogenous
MMP-2 after BAG2 knockdown (Figure 6I). Interestingly, immu-
noblotting using concentrated supernatants demonstrated that
only pro-CTSB was detected in the supernatants of control
TNBC cells, whereas BAG2 depletion substantially reduced the
expression level of pro-CTSB in the supernatants of TNBC cells
(Figure 6J). More strikingly, increased extracellular levels of both
BAG2 and pro-CTSB were observed when BAG2 was overex-2960 Cell Reports 21, 2952–2964, December 5, 2017pressed in MCF10AT1 cells, which express low levels of BAG2
mRNA and protein (Figure 6K), and serum levels of BAG2 were
significantly higher in patients with breast cancer than in healthy
volunteers (p = 0.0013), suggesting that BAG2 secretion may
also serve as a predictive factor in breast cancer (Figure 6L).
Taken together, these results indicate that BAG2 regulates not
only the interaction between pro-CTSB and annexin II tetramers
on the TNBC cell surface but also pro-CTSB secretion, which in-
duces the degradation of ECM components by activating extra-
cellular proteases, eventually contributing to the promotion of
cancer metastasis.
BAG2 Controls Pro-CTSB Trafficking through the trans-
Golgi Network
Considering that pro-CTSB is rapidly secreted from the cell via
the secretory pathway, which is mainly associated with the
trans-Golgi network (TGN) (Linke et al., 2002), we initially inves-
tigated the distribution of pro-CTSB in subcellular organelles.
BAG2 and pro-CTSB were abundant in the Golgi/ER fraction in
control cells, whereas depletion of BAG2 led to increased lyso-
somal distribution of the SC form of CTSB and LAMP-1 (Fig-
ure 7A). Most intriguingly, BAG2 knockdown led to significantly
elevated Golgi/ER distribution of pro-CTSB and TGN38, a TGN
marker, without affecting the expression of PDI-1, an ERmarker,
and GM130, a cis-Golgi marker, suggesting that extracellular
trafficking of both pro-CTSB and TGN38 might be interrupted
by the depletion of BAG2. This was further supported by an
immunofluorescence assay showing that TGN38 was broadly
co-localized with CTSB and BAG2 in the cytoplasm of control
cells, whereas BAG2 depletion markedly induced retrograde
movement of both CTSB and TGN38 from the cell periphery to
the perinuclear region (Figure 7B). Considering that BAG2 may
regulate anterograde trafficking of TGN38-positive vesicles,
which contain pro-CTSB, toward the cell periphery and that
Golgi extension reflects TGN38 trafficking to promote vesicular
release, we hypothesized that BAG2-mediated secretion of
pro-CTSB may be controlled by the secretory capacity of
TGN38-positive vesicles. Therefore, we investigatedGolgi vesic-
ular release by tracking TGN38-positive vesicles enclosing pro-
CTSB in the cytoplasm through a Golgi exit assay. Interestingly,
BAG2 depletion significantly reduced the trafficking of pro-
CTSB-containing TGN38-positive vesicles from theGolgi toward
the cell periphery (Figure 7C), consistent with previous results
that pro-CTSB was not detected on the cell membrane or extra-
cellular space upon BAG2 depletion as a consequence of
impaired TGN function. Taken together, our findings suggest
that BAG2 facilitates the secretion of pro-CTSB through
TGN38-positive vesicles, thereby promoting the metastatic po-
tential of TNBC cells by enhancing the secretory capacity of
the Golgi (Figure 7D).
DISCUSSION
In this study, our findings suggest a unique role for BAG2 as
a crucial regulator of the dual functions of its client protein,
CTSB, facilitating the progression of TNBC. BAG2 is highly ex-
pressed in human TNBC cell lines and TNBC patient cohorts
and is closely associated with recurrence- and metastasis-free
Figure 6. BAG2 Interacts with the Pro-CTSB/Annexin II Complex on the Surface of TNBC Cells
(A) Immunoblot analysis showing biotinylated plasma membrane fraction in control and BAG2-depleted MDA-MB-231.
(B) Immunoprecipitation assay for endogenous interaction between BAG2 and annexin II along with pro-CTSB in MDA-MB-231 cells.
(C and D) Immunoprecipitation assay to verify the interaction region between BAG2 and annexin II (C) or S100A10 (D).
(E and F) GST pull-down assay of Myc-tagged BAG2 and C-terminal hemagglutinin (HA)-tagged annexin II (E) or GFP-tagged S100A10 (F) bound to the
GST-fused propeptide region (PPR) of pro-CTSB.
(G) Immunoprecipitation assay for endogenous interaction between CTSB and annexin II in control and BAG2-depleted MDA-MB-231 cells.
(H) Immunoblot analysis showing CTSB, BAG2, and annexin II bound to the cell surface in a Ca2+-dependent manner.
(I) The supernatants were analyzed by gelatin zymography for MMP-2 activation.
(J) Immunoblot analysis showing secreted pro-CTSB and BAG2 in conditioned media of control and BAG2-depleted TNBC cells.
(K) Immunoblot analysis showing secreted pro-CTSB and BAG2 in conditioned media of control and BAG2-overexpressed MCF10AT1 cells.
(L) ELISA analysis showing BAG2 protein levels in the serums of healthy volunteers (n = 17) andmalignant breast cancer patients (n = 76). p valueswere calculated
by unpaired two-tailed Student’s t tests. Data represent means ± SD of three independent experiments.survival, implying that patients with high BAG2 expression are at
risk of developing recurrence andmetastatic disease.Mechanis-
tically, BAG2 has been shown to impair auto-cleavage process-
ing of pro-CTSB and facilitate the secretion of pro-CTSB through
TGN-positive vesicles, eventually resulting in enhanced cell
death and attenuated metastasis.
Although it is recognized that BAG2 is predominantly localized
in the cytoplasm, a recent study reported that BAG2 binds to
mutant p53 proteins and promotes their translocation from the
cytoplasm to the nucleus in various cancer cells (Yue et al.,2015). Considering that mutant p53 is the most frequent genetic
alteration found in breast cancer and is positively associatedwith
more aggressive breast cancers, it is possible that BAG2may be
predominantly localized in the nucleus of TNBC cells. Unexpect-
edly, BAG2 was mainly localized in the cytoplasm, regardless of
either breast cancer subtype or mutant p53 status, as demon-
strated by subcellular fractionation and confocal imaging (data
not shown). Therefore, our findings suggest that a cytoplasmic
function of BAG2 overexpressed in TNBC cells promotes tumor-
igenesis and metastasis, regardless of mutant p53 status.Cell Reports 21, 2952–2964, December 5, 2017 2961
Figure 7. BAG2 Facilitates Pro-CTSB Secretion through Regulation of TGN Trafficking
(A) Immunoblot analysis showing lysosome and Golgi/ER fractions of control and BAG2-depleted MDA-MB-231 cells.
(B) Immunofluorescence analysis of endogenous TGN38, CTSB, and BAG2.
(C) Golgi exit assay of control and BAG2-depleted MDA-MB-231 cells.
(D) Schematic diagram of pro-CTSB trafficking regulated by BAG2.Based on proteomic analysis, we identified CTSB as a BAG2
client protein. Many studies have shown that redistribution of
CTSB in cancer cells can affect the ECM directly by causing its
proteolytic degradation or indirectly by activating other extracel-
lular-matrix-degrading proteases, such as uPA and MMPs in
acidic tumor environments, eventually facilitating tumor progres-
sion and metastasis (Gondi and Rao, 2013). On the contrary,
recent studies have also reported that CTSB contributes to the
induction of autophagy/apoptosis, linking the pro-apoptotic
role of cytosolic CTSB as an initiating protease to the activation
of Bid or caspases in lysosome-mediated cell death (Chwieralski
et al., 2006). Therefore, considering these likely context-depen-
dent dual roles of CTSB as either a tumor promoter or tumor
suppressor, the identification of regulators and the specific
mechanisms controlling the dual functions of CTSB is crucial.
In this study, we identified BAG2 as a regulator of the dual func-
tions of CTSB. First, we found that BAG2 depletion markedly
increased the active/mature SC form of CTSB, whereas it
induced a decrease in the pro- and DC forms of CTSB. However,
given that either the DC form or both the SC and DC forms of
CTSB are active in purified CTSB (Moin et al., 1992), the relative
activity of the two forms of CTSB may be observed in a context-
dependent manner.2962 Cell Reports 21, 2952–2964, December 5, 2017In addition, we demonstrated that BAG2 knockdown led to
the release of lysosomal active SC CTSB into the cytosol and
a subsequent increase in executioner caspase-3-mediated
apoptosis, indicating that BAG2 may prevent the growth inhibi-
tion of TNBC cells by protecting the conversion of inactive pro-
CTSB to the active SC form. Besides the pro-apoptotic role
of intracellular mature SC CTSB, pro-CTSB is constitutively
secreted into the extracellular space in malignant tumors. This
secreted pro-CTSB can be activated by other membrane-asso-
ciated proteases and is bound on the tumor cell surface; subse-
quently, membrane-associated pro-CTSB can be activated by
other soluble proteases, thereby degrading ECM components
and facilitating metastasis (Gondi and Rao, 2013; Mohamed
and Sloane, 2006). It is also known that the binding of pro-
CTSB to the annexin II tetramer, which is a Ca2+-dependent
phospholipid-binding protein that is known to be upregulated
on the surface of tumor cells, results in the activation of pro-
CTSB on the tumor cell surface (Mai et al., 2000). In this regard,
we confirmed that BAG2 interacted with annexin II along with the
PPR of pro-CTSB and that its complex was present on the cell
surface in a Ca2+-dependent manner, suggesting that BAG2
may mediate a link between membrane association and activa-
tion of pro-CTSB. Furthermore, localization of CTSB to the cell
surface has been associated with Ras mutations (Cavallo-
Medved et al., 2003). However, considering that BAG2 was
under-expressed in Ras-mutated T47D and MCF10AT1 cells,
which are nonaggressive breast cancer cells, the expression
level of BAG2 does not seem to be dependent on mutant Ras
status in breast cancer cells.
Moreover, our findings raise questions regarding how BAG2
regulates the trafficking of pro-CTSB to the cell periphery. Previ-
ous studies have indicated that the secretion of the pro-form as
well as the SC form of CTSB appears to be facilitated by lyso-
somal exocytosis (Keppler and Sloane, 1996; Tu et al., 2008).
However, our results suggest that BAG2may facilitate trafficking
of pro-CTSB through TGN38-positive vesicles rather than
by lysosomal exocytosis. Indeed, BAG2-depleted TNBC cells
demonstrated concentrated distribution of pro-CTSB and
TGN38 at the perinuclear region, whereas pro-CTSB was more
diffusely co-localized with TGN38 toward the cell periphery in
the control cells. This observation was further supported by a
Golgi exit assay, corroborating the presence of TGN38-positive
vesicles that enclose pro-CTSB during its trafficking from the
TGN. Therefore, BAG2 is responsible for the localization and
activation of pro-CTSB on the external cell surface of TNBC cells
during tumor metastasis. It also was reported that annexin II me-
diates plasma membrane fusion of TGN38-positive vesicles via
its interaction with soluble N-ethylmaleimide-sensitive factor
attachment protein receptors (SNAREs) in the regulation of
lung surfactant secretion (Dassah et al., 2014; Wang et al.,
2007). In this regard, it is possible that BAG2 may participate in
the regulated exocytosis of pro-CTSB through interactions with
SNAREs, because BAG2 binds to annexin II and regulates traf-
ficking of TGN38-positive vesicles containing pro-CTSB to the
plasma membrane. However, considering that BAG2 depletion
did not inhibit translocation of annexin II on the cell surface,
the ability of BAG2 to control trafficking of TGN38-positive ves-
icles containing pro-CTSB seems to be independent of an-
nexin-II-mediated exocytosis.
Our findings also suggest that BAG2 prevents the conver-
sion of the immature pro-form of CTSB to the mature SC
form through its interaction with pro-CTSB at the PPR of the
N terminus. This PPR has been shown to inhibit the enzyme
activity of CTSB by masking the active-site cleft, which is
required for substrate hydrolysis (Podobnik et al., 1997). In
addition, the two-turn a helix (Met-P51 to Cyc-P58) of the
PPR sits on top of the active site and includes the intermediate
starting site (Arg-P56 to Leu-P57) for auto-catalytic process-
ing, although it is unclear whether propeptide removal is
accomplished in a single step or through one or more interme-
diates (Chagas et al., 1996; Quraishi and Storer, 2001). Inter-
estingly, we found that that residues 51–58 of the two-turn
a helix of the propeptide region of pro-CTSB is responsible
for the interaction with the BAG domain of BAG2, but the
well-established cleavage sites (Met-P72 to Phe-P73) of pro-
CTSB near the pro/mature junction (Gly-P59 to Lys-P78) is
not involved in this interaction. Altogether, BAG2 seems to
play a negative role in the pro-apoptotic activation of intracel-
lular mature CTSB by inhibiting auto-proteolytic processing of
pro-CTSB through its interaction with pro-CTSB at the inter-
mediate sites of the PPR.In conclusion, our results present a mechanism by which
BAG2 regulates the dual functions of CTSB by controlling the
auto-cleavage processing of CTSB, thereby exerting a unique
function in TNBC progression. In addition, given that the onco-
genic function of CTSB is strongly linked to breast cancer
progression, our findings highlight BAG2 as a promising and
therapeutic target for TNBC.
EXPERIMENTAL PROCEDURES
Cell cultures, reagents, antibodies, and transfections are described in detail in
Supplemental Experimental Procedures.
Public Transcriptomic Data Analysis
We obtained two types of transcriptomic data (RNA-sequencing datasets)
from the GDC Data Portal (https://portal.gdc.cancer.gov). We used fragment
per kilobase exon model per million mapped reads (FPKM) values normalized
by upper quartile (UQ) normalization for RNA sequencing. One-way ANOVA
was performed by comparing RNA-sequencing data of the four subtypes of
breast cancer (luminal A, luminal B, HER2 positive, and TNBC) for five BAG
family genes (BAG1, BAG2, BAG3, BAG4, and BAG5). The public microarray
datasets (GEO: GSE41313, GSE2034, GSE5460, and GSE26971) were down-
loaded from NCBI’s GEO.
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